Comparative Pharmacology
Head-to-head clinical analysis: ENHERTU versus IDVYNSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENHERTU versus IDVYNSO.
ENHERTU vs IDVYNSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody-drug conjugate (ADC). The antibody is a humanized anti-HER2 IgG1, and the small molecule DXd is a topoisomerase I inhibitor. Upon binding to HER2 on tumor cells, the ADC undergoes internalization and intracellular cleavage, releasing DXd which causes DNA damage and apoptotic cell death.
IDVYNSO is a selective dopamine D3 receptor antagonist, which modulates dopaminergic neurotransmission in the mesolimbic pathway.
5.4 mg/kg intravenously every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
5 mg/kg IV once daily for 14 days; then 2.5 mg/kg IV once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 5.5 days (range 4.5–7.5 days) for the antibody-drug conjugate, supporting every-3-week dosing.
Terminal elimination half-life is 12–18 hours, supporting twice-daily dosing in patients with normal renal function.
Primarily biliary/fecal excretion (approximately 95% as unchanged drug); renal excretion is negligible (<1%).
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%, with the remainder metabolized.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent